A Phase 1, Open-Label Study of the Biodistribution, Pharmacokinetics, and Dosimetry of ²²³Ra-Dichloride in Patients with Hormone-Refractory Prostate Cancer and Skeletal Metastases

Abstract

A wide range of interpatient absorbed doses was delivered to normal organs. Intrapatient absorbed doses were significantly correlated between the 2 administrations for any given patient. The lack of gastrointestinal toxicity is likely due to the low absorbed doses delivered to the gut wall from the gut contents. The lack of adverse myelotoxicity implies that the absorbed dose delivered from the circulating activity may be a more relevant guide to the potential for marrow toxicity than that due to activity on the bone surfaces.